^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    The following regimens added as Other Recommended for squamous cell carcinoma….Tremelimumab-actl + durvalumab + carboplatin + albumin-bound paclitaxel…Tremelimumab-actl + durvalumab + (carboplatin or cisplatin) + gemcitabine
    Secondary therapy:
    carboplatin + gemcitabine; cisplatin + gemcitabine; carboplatin + albumin-bound paclitaxel